Chemed (CHE) Q2 Earnings Miss Estimates

Core Viewpoint - Chemed reported quarterly earnings of $4.27 per share, missing the Zacks Consensus Estimate of $4.78 per share, and down from $5.47 per share a year ago, indicating a negative earnings surprise of -10.67% [1][2] Financial Performance - The company posted revenues of $618.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.45% and up from $595.88 million year-over-year [3] - Chemed has exceeded consensus revenue estimates three times over the last four quarters [3] Stock Performance - Chemed shares have declined approximately 12% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [4] - The current Zacks Rank for Chemed is 5 (Strong Sell), indicating expectations of underperformance in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $5.69 on revenues of $632.43 million, and for the current fiscal year, it is $23.09 on revenues of $2.56 billion [8] - The trend of estimate revisions for Chemed was unfavorable prior to the earnings release, which may impact future stock performance [7] Industry Context - Chemed operates within the Medical - Outpatient and Home Healthcare industry, which is currently ranked in the top 38% of over 250 Zacks industries [9] - The performance of Chemed's stock may be influenced by the overall outlook of the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9]